INTRODUCTION {#s1}
============

Cervical cancer is a leading cause of cancer deaths in women worldwide, with an estimated 528,000 new cases and 266,000 deaths annually; 85% occur in developing countries \[[@R1], [@R2]\]. As a developing country, China has a high incidence of cervical cancer, 7.5/100,000 women, and mortality 3.4/100,000 women, especially in rural areas because of lack of proper screening \[[@R3]\]. The incidence of cervical cancer has reached 81/100,000 people in some areas in China \[[@R4]\]. By 2030, cervical cancer is expected to be responsible for the death of 474,000 women annually, with more than 95% of these deaths anticipated to occur in low- and middle-income countries \[[@R5]\]. Thus, establishing a proper screening strategy is of great importance to reduce the cancer burden in China.

The most widely used screening methods for cervical cancer are the cytology-based Pap smear and high-risk human papillomavirus (hrHPV) testing. However, both methods have drawbacks. In one study, of more than 60,000 women, cytology-based Pap smear screening did not detect almost half of the cases of cervical intraepithelial neoplasia 2 (CIN2), CIN3 and cancer (CIN2+) and only 20% of the women with an abnormal Pap smear had histologically confirmed CIN2+ \[[@R6]\]. Moreover, cytology testing is often subjective for a great number of professional cytologists. HrHPV testing of cervical scrapings can improve the sensitivity of cervical screening \[[@R7], [@R8]\]; however, the lifetime risk of hrHPV infection is estimated to be about 80% \[[@R9]\] and the screening hrHPV test cannot discriminate between infections that would transform into cancer and transient infections. Such a less specific screening test may lead to a substantially heavy burden on health care resources, such as unnecessary referral to colposcopy. To avoid missed diagnoses and over-diagnoses, other triage and/or complementary biomarkers that are molecularly based and not morphology based are urgently needed.

DNA hypermethylation of the promoter and 5′ region of tumor suppressor genes is an epigenetic modification that may be involved in the early phase of carcinogenesis, including cervical carcinogenesis \[[@R10]--[@R13]\]. Epigenetic changes occur during each of stage of cervical cancer \[[@R14]\], and various genes are silenced by promoter methylation at distinct stages in the transformation process \[[@R15], [@R16]\]. The accumulation of epigenetic alterations in the host genome promote the progression to invasive cervical cancer \[[@R17]\]. The most appropriate screening biomarkers of DNA methylation in cervical carcinogenesis appear during the progression to high-grade dysplasia. A series of studies \[[@R10], [@R14], [@R18], [@R19]\] reviewed the epigenetic alterations in premalignant and malignant lesions of the cervix but were heterogenous and results were inconsistent for most genes. Methylation frequencies for the same gene vary widely among studies because of the different loci chosen \[[@R20]\], different genetic backgrounds of various populations \[[@R21], [@R22]\], specific features of assay protocols, or other unidentified factors.

In the present study, we aimed to identify highly distinguishable DNA methylation loci of genes that may be clinically practical as biomarkers of cervical cancer, especially in geographic locations where quality-controlled cytology testing is absent and a follow-up strategy for HPV-positive women is not defined \[[@R23]\]. Previously reported methylation status in cervical neoplasia identified cyclin A1 (*CCNA1*) \[[@R24]--[@R26]\], cell adhesion molecule 1 (*CADM1*) \[[@R20], [@R26]--[@R28]\], death-associated protein kinase 1 (*DAPK1*) \[[@R25], [@R26], [@R29]\] and junctional adhesion molecule 3 (*JAM3*) \[[@R13]\] as the most discriminating and stable biomarkers. From microarray data from The Cancer Genome Atlas and a review of the literature to identify the most discriminating loci, we chose various loci of these 4 genes for in-depth investigation by methylation-specific PCR (MSP) of cervical cancer and normal cervical tissue. The markers were further evaluated and confirmed with cervical scrapings from two colposcopy referral studies including 267 and 224 cervical scrapings, respectively (Predictors 1 \[P1\] and Predictors 2 \[P2\]), and the most promising marker was evaluated to identify its potential as a triage or complementary marker in hrHPV or cytology testing. Finally, the discriminating marker was validated by pyrosequencing and assessed for potential to triage the controversial CIN2.

RESULTS {#s2}
=======

Sample characteristics {#s2_1}
----------------------

Clinicopathological data for tissue specimens are in Table [1](#T1){ref-type="table"}. Clinicopathological data and available hrHPV and cytology results for cervical scrapings are in Table [2](#T2){ref-type="table"}.

###### Clinicopathological characteristics of the tissue specimen

                       No.
  -------------------- ---------------
  Total number         43
  Age (Mean ± SD)      45.75 ± 10.21
  FIGO                 
  IA                   9
   IB                  11
   IIA                 6
   IIB                 4
   IIIA                5
   IIIB                6
   IV                  2
  Pathological type    
  Squamous carcinoma   35
  Adenocarcinoma       7
   Others              1

###### Clinicopathological data of patients with scrapings and the relative available hrHPV testing and cytology testing results

                    Predictors 1    Predictors 2                                                                                                               
  ----------------- --------------- -------------- --------------- -------------- --------------- --------------- -------------- -------------- -------------- --------------
  Total number      53              59             72              63             20              70              49             51             33             14
  Age (Mean ± SD)   44.35 ± 10.39   41.88 ± 8.78   38.31 ± 10.42   40.39 ± 8.49   50.29 ± 11.86   41.84 ± 10.05   40.20 ± 6.99   38.39 ± 8.01   39.61 ± 7.74   46.38 ± 8.73
  HrHPV                                                                                                                                                        
   Positive         39              41             62              44             9               55              41             41             24             7
   Negative         6               10             1               1              0               5               1              0              1              0
  Cytology                                                                                                                                                     
   NILM             10              16             10              3              1               21              19             9              5              2
   ASCUS            16              19             25              8              3               30              22             20             8              2
   LSIL             18              9              12              6              1               8               6              7              6              1
   ASC-H            3               2              5               14             1               2               2              3              4              3
   HSIL             3               1              6               9              2               3               0              6              8              1

MSP of normal cervical and cervical cancer tissue {#s2_2}
-------------------------------------------------

MSP analysis of specimens from 27 patients with normal cervical tissue and 43 with cancer tissue is in Table [3](#T3){ref-type="table"}. Promising markers were chosen on the basis of *P* value and comparison of methylation frequency. Liquid-based cytology specimens were the most frequent specimens used for cervical cancer screening and triage. The specific loci for each gene were labeled M1, M2, etc. The first 5 gene loci (*CADM1*-M2, *CADM1*-M8, *DAPK1*-M2, *DAPK1*-M3, and *JAM3*-M4) selected from the initial 27 markers were further evaluated by quantitative MSP (QMSP) in cervical scrapings (Figure [1](#F1){ref-type="fig"}). The methylation frequency for these loci was significantly higher in cervical cancer than normal cervical tissue (Table [3](#T3){ref-type="table"}).

###### Methylation frequency in tissue specimen obtained from patients with normal cervix or cervical cancer

  Gene-locus   Cancer   Normal   *P*[^a^](#tfn_001){ref-type="table-fn"}
  ------------ -------- -------- -----------------------------------------
  *CADM1*-M2   28/43    6/27     \< 0.001
  *CADM1*-M8   32/43    0/27     \< 0.001
  *DAPK1*-M2   30/43    3/27     \< 0.001
  *DAPK1*-M3   33/43    2/27     \< 0.001
  *JAM3*-M4    37/43    2/27     \< 0.001

*P* value was calculated by chi-square test. If groups were too small, Fisher\'s exact test was applied

![Methylation status of candidate genes in representative examples\
(**A**) *CADM1*-M2. (**B**) *CADM1*-M8. (**C**) *DAPK1*-M2. (**D**) *DAPK1*-M3. (**E**) *JAM3*-M4. Abbreviations: C: cervical cancer. N: normal cervical tissue. M-co: bisulfite-converted methylated DNA. U-co: bisulfite-converted unmethylated DNA. NTC: no-template control. M: methylated-specific primer sets; U: unmethylated-specific primer sets.](oncotarget-06-44373-g001){#F1}

QMSP of cervical scrapings as a screening biomarker {#s2_3}
---------------------------------------------------

QMSP for *CADM1*-M2, *CADM1*-M8, *DAPK1*-M2, *DAPK1*-M3, and *JAM3*-M4 involved cervical scrapings from a colposcopy referral study (P1) of 267 patients. In general, the methylation ratio increased with increasing lesion severity. Particularly, *JAM3*-M4 was most discriminative marker (Figure [2](#F2){ref-type="fig"}).

![Methylation ratio in cervical scrapings from patients referred for colposcopy (n = 267)\
Dot plots illustrate the methylation ratio distributions. Methylation ratio of (**A**) *CADM1*-M2, (**B**) *CADM1*-M8, (**C**) *DAPK1*-M2, (**D**) *DAPK1*-M3, (**E**) *JAM3*-M4. CIN1−: no neoplasia and CIN1. CIN3+: CIN3 and cancer cases. \**P* \< 0.05, \*\**P* \< 0.01. Each point represents one sample; the horizontal line is the mean and whiskers are SEM.](oncotarget-06-44373-g002){#F2}

To further investigate the data, we used different classifications for diagnostic groups. CIN2+/CIN1− and CIN3+/CIN2− were the classifications when the end point was CIN2 and CIN3, respectively. Because of the controversy with CIN2 itself, we evaluated the classification CIN3+/CIN1−. A logistic regression model was used to explore the predictive power of methylation of the 5 loci with different diagnostic classifications. For the CIN3+/CIN1− and CIN3+/CIN2− classifications, *JAM3*-M4 had adequate predictive power. Other genes did not add substantial information for discrimination. For the CIN2+/CIN1− classification, *CADM1*-M8 (*P* = 0.001), *DAPK1*-M3 (*P* = 0.038) and *JAM3*-M4 (*P* = 0.011) showed the best discriminating power. However, the area under the receiver operating characteristic curve (AUC) for the 3 genes combined (AUC = 0.806) was only slightly higher than that with *JAM3*-M4 alone (AUC = 0.793). Therefore, in the following analysis, we evaluated *JAM3*-M4 alone with the diagnostic groups in P1 (Figure [3A](#F3){ref-type="fig"}, [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). The AUC for *JAM3*-M4 for CIN3+/CIN1−, CIN3+/CIN2− and CIN2+/CIN1− classifications was 0.907, 0.860 and 0.793, respectively. The AUC for *JAM3*-M4 was reproducible in the two studies of P1 and P2, with similar AUC of 0.900, 0.870 and 0.765 for CIN3+/CIN1−, CIN3+/CIN2− and CIN2+/CIN1− classifications in P2 (Figure [4A](#F4){ref-type="fig"}).

![Receiver operating characteristic (ROC) curves of the discriminating performance of JAM3-M4 in different classifications of diagnostic groups in P1\
The area under the ROC curve (AUC) was used to estimate accuracy. *JAM3*-M4 performance for (**A**) all patients, (**B**) patients with abnormal cytology result, (**C**) patients with atypical squamous cells of unknown significance (ASCUS), (**D**) patients with low-grade squamous intraepithelial lesion (LSIL), (**E**) patients positive for high-risk human papillomavirus (hrHPV-positive). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; 95% CI, 95% confidence interval.](oncotarget-06-44373-g003){#F3}

![ROC curves of the discriminating performance of JAM3-M4 in different classifications of diagnostic groups in P2\
The area under the ROC curve (AUC) was used to estimate accuracy. *JAM3*-M4 performance for (**A**) all patients, (**B**) patients with abnormal cytology result, (**C**) patients with atypical squamous cells of unknown significance (ASCUS), (**D**) patients with low-grade squamous intraepithelial lesion (LSIL), (**E**) patients positive for high-risk human papillomavirus (hrHPV-positive). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001; 95% CI, 95% confidence interval.](oncotarget-06-44373-g004){#F4}

QMSP of *JAM3*-M4 as a triage marker in patients with abnormal cytology smear results and hrHPV-positive patients {#s2_4}
-----------------------------------------------------------------------------------------------------------------

With *JAM3*-M4 used as a triage marker for patients with abnormal cytology smear results (the cutoff was ≥ atypical squamous cells of unknown significance \[ASCUS\]), the AUC values were 0.911, 0.843 and 0.810 and 0.890, 0.840 and 0.795 for CIN3+/CIN1−, CIN3+/CIN2− and CIN2+/CIN1− classifications in P1 and P2, respectively (Figures [3B](#F3){ref-type="fig"}, [4B](#F4){ref-type="fig"}). The sensitivity was slightly decreased and the specificity increased as compared with the triage performance of hrHPV, especially for the CIN3+/CIN1− and CIN3+/CIN2− classifications ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The positive predictive value (PPV) and negative predictive value (NPV) were both increased for all classifications ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

We divided patients with abnormal cytology results into ASCUS and low-grade squamous intraepithelial lesion (LSIL) subgroups and compared the diagnostic performance of *JAM3*-M4 to the triage performance of hrHPV testing (Figures [3C](#F3){ref-type="fig"}, [4C](#F4){ref-type="fig"}, [3D](#F3){ref-type="fig"}, [4D](#F4){ref-type="fig"}, Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). For both ASCUS and LSIL subgroups, the specificity and PPV of *JAM3*-M4 was increased significantly for all classification groups, at the cost of a moderate decrease in sensitivity and NPV for ASCUS patients (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). Patients with ASCUS who were \< 30 years old (*n* = 19) were all hrHPV-positive; 15 had CIN1−, all negative for the *JAM3*-M4 marker.

###### Triage performance of methylation marker for patients with hrHPV positive and patients with cytology result of ASCUS and LSIL in P1

                      CIN3+/CIN1−   CIN3+/CIN2−   CIN2+/CIN1−                                                                       
  ------------------- ------------- ------------- ------------- -------- -------- ------- ------- -------- -------- ------- ------- --------
  ASCUS →HPV          100.00        21.88         26.47         100.00   100.00   12.50   15.52   100.00   100.00   21.88   56.90   100.00
  ASCUS →*JAM3*-M4    72.73         81.82         57.14         90.00    72.73    70.69   32.00   93.18    52.78    81.82   76.00   61.36
  LSIL →HPV           100.00        15.38         18.52         100.00   100.00   10.81   13.16   100.00   100.00   15.38   42.10   100.00
  LSIL →*JAM3*-M4     100.00        85.18         63.64         100.00   100.00   80.00   46.67   100.00   63.16    85.18   75.00   76.67
  HPV(+) →Cytology    91.67         30.67         38.82         88.46    91.67    25.58   25.58   91.67    85.56    30.67   59.69   63.89
  HPV(+) →*JAM3*-M4   86.79         87.65         82.14         91.02    86.79    73.43   54.76   93.75    65.22    87.65   88.24   63.96

###### Triage performance of methylation marker for patients with hrHPV positive and patients with cytology result of ASCUS and LSIL in P2

                                                 CIN3+/CIN1−   CIN3+/CIN2−   CIN2+/CIN1−                                                                       
  ---------------------------------------------- ------------- ------------- ------------- -------- -------- ------- ------- -------- -------- ------- ------- --------
  ASCUS →HPV                                     100.00        11.36         18.75         100.00   100.00   7.81    13.24   100.00   100.00   11.36   42.65   100.00
  ASCUS →*JAM3*-M4                               70.00         90.38         58.33         94.00    70.00    81.94   35.00   95.16    50.00    90.38   75.00   75.81
  LSIL →HPV[\*](#tfn_002){ref-type="table-fn"}   100.00        0.00          28.57         \-       100.00   0.00    25.00   \-       100.00   0.00    37.50   \-
  LSIL →*JAM3*-M4                                100.00        78.57         70.00         100.00   100.00   71.43   53.85   100.00   71.43    78.57   76.92   73.33
  HPV(+) →Cytology                               78.57         43.96         30.14         86.96    78.57    38.58   22.00   89.09    76.56    43.96   49.00   72.73
  HPV(+) →*JAM3*-M4                              80.64         89.58         71.43         93.48    80.64    80.29   48.08   94.83    58.33    89.58   80.77   74.14

All the patients with cytology result of LSIL were hrHPV positive.

With *JAM3*-M4 used as a triage marker for hrHPV-positive patients, the AUC was 0.904, 0.846 and 0.771 and 0.871, 0.848 and 0.711 for CIN3+/CIN1−, CIN3+/CIN2− and CIN2+/CIN1− classifications in P1 and P2, respectively (Figures [3E](#F3){ref-type="fig"}, [4E](#F4){ref-type="fig"}). *JAM3*-M4 showed slightly decreased sensitivity, with increased specificity, PPV, and NPV as compared with triage performance of cytology testing, especially for CIN3+/CIN1− and CIN3+/CIN2− classifications (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}).

QMSP of *JAM3*-M4 as a complementary marker in cytology or hrHPV testing {#s2_5}
------------------------------------------------------------------------

With *JAM3*-M4 used as a complementary marker in hrHPV or cytology testing, the sensitivity was slightly lower and the specificity and PPV was increased greatly as compared with the combination of cytology and hrHPV testing in P1 ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). As most likely used in clinical practice, *JAM3*-M4 as a complementary marker in cytology testing was further confirmed in P2 ([Supplementary Table 4](#SD1){ref-type="supplementary-material"}).

Pyrosequencing validation of the methylation status of *JAM3*-M4 {#s2_6}
----------------------------------------------------------------

Methylation levels across the CpG sites for *JAM3*-M4 were relatively stable. The mean methylation ratio of the 5 representative CpG sites was 4.94 ± 1.20, 4.36 ± 2.30, 5.37 ± 1.57, 10.68 ± 6.08, 18.49 ± 16.91 and 52.70 ± 14.71 for the patient groups: negative for intraepithelial lesion and malignancy (NILM) (*n* = 8), CIN1 (*n* = 10), CIN2 QMSP-negative (QM(−)) (*n* = 9), CIN2 QM(+) (*n* = 8), CIN3 (*n* = 10) and cancer (*n* = 9) (Figure [5A](#F5){ref-type="fig"}). The mean methylation ratio of corresponding specimens detected by QMSP and pyrosequencing did not differ (data not shown). Pyrosequencing revealed significant differences between CIN2 QM(−) and CIN2 QM(+), CIN3 and cancer (Figure [5B](#F5){ref-type="fig"}).

![Pyrosequencing analysis of representative loci in JAM3-M4\
(**A**) Methylation status of representive loci in representative samples from patient groups: negative for intraepithelial lesion and malignancy (NILM), cervical intraepithelial neoplasia 1 (CIN1), CIN2 QMSP-negative \[QM(−)\], CIN2 QM(+), CIN3, and cancer confirmed by pyrosequencing. (**B**) Box-plot of the methylation percentage for *JAM3*-M4 for loci for the 6 groups, with statistical analysis between every 2 neighbouring groups. (**C**) Box-plot of the methylation percentage for *JAM3*-M4 for loci for diagnostic groups (CIN1−, CIN2, CIN3+) consistent with the QMSP analysis. Horizontal line is median, whiskers are 5th and 95th percentiles, and lower and upper box boundaries are 25th and 75th percentiles. \**P* \< 0.05, \*\**P* \< 0.01.](oncotarget-06-44373-g005){#F5}

To be consistent with the QMSP analysis of the loci, we examined *JAM3*-M4 discrimination among relevant diagnostic groups (CIN1−, CIN2, CIN3+) and found that it was significantly discriminative (Figure [5C](#F5){ref-type="fig"}).

Discriminating performance of *JAM3*-M4 for CIN2 patients {#s2_7}
---------------------------------------------------------

Immunohistochemistry analysis of P16 and the corresponding pyrosequencing analysis in samples from representative CIN2 patients are in Figure [6](#F6){ref-type="fig"}. The rate of positive staining for P16 was 69.9% and the rate of positive methylation for *JAM3*-M4 was 48.8%. The methylation ratio for *JAM3*-M4 between LSIL and HSIL was significant (*P* = 0.03). The coincidence rate was 60.5% (*P* = 0.119).

![Immunohistochemical staining of P16 in samples from patients with histological diagnosis of CIN2\
(**A**) Hematoxylin and eosin staining (H/E) for LSIL, and (**B**) P16, negative in LSIL tissue. (**C**) Pyrosequencing analysis of LSIL. (**D**) H/E staining of HSIL, and (**E**) P16, positive in HSIL tissue. (**F**) Pyrosequencing analysis of HSIL. Original magnification, A, B, C, D, × 200.](oncotarget-06-44373-g006){#F6}

DISCUSSION {#s3}
==========

We used both cervical tissue specimens and cervical scrapings for an in-depth analysis of the methylation status of different loci in candidate gene promoters and their possible diagnostic relevance in cervical neoplasia. *JAM3*-M4 showed good performance in two different and independent studies (P1 and P2) but also with three different diagnostic classifications. *JAM3*-M4 methylation may be a marker for triage and a complementary marker in clinical practice.

Detecting and identifying cervical preneoplasia is important to halt the progression to cancer. As a promising methylation marker, *JAM3* has been investigated for discriminating performance \[[@R12], [@R13], [@R30], [@R31]\]. However, the studies investigated the same locus in different media, including conventional liquid-based cytology, self-sampled brush material and cervico-vaginal lavage. We compared several loci of the same gene and found a new locus, *JAM3*-M4, with promising predictive power in primary screening of cervical neoplasia. We also investigated its combined application with the most widely used screening methods -- hrHPV and cytology-based Pap smear testing.

Infection with HPV causes cervical preneoplasia and neoplasia \[[@R32]\]. Depending on the hrHPV testing, the diagnosis can cause over-diagnosis and over-treatment. Unnecessary referral to the gynecologist leads to anxiety, distress \[[@R33]\], and even anger and resentment with a perceived threat to life and/or fertility \[[@R34]\]. Compared to the widely used triage test--cytology after hrHPV testing --*JAM3*-M4 showed increased specificity and PPV. Thus, most unnecessary referrals for colposcopy could be avoided. In addition, with the acceptable PPV of *JAM3*-M4, hrHPV-positive patients also positive for *JAM3*-M4 could be directly referred to colposcopy.

Considering cost-effectiveness, long-term application and high specificity for serious lesions, cytomorphological appraisal is still widely used as primary screening. Developing countries lack quality-controlled cytology testing, and the diagnostic performance is unsatisfactory. The addition of a methylation marker could improve the predictive power even better than combined with HPV testing. Considering the low sensitivity of cytology testing in population-based screening, use of *JAM3*-M4 could be complementary to cytology testing to improve performance, especially the specificity and PPV.

Patients with ASCUS or LSIL account for a considerable proportion of biopsy-confirmed CIN2+ cases \[[@R35]\]. However, the underlying risk of ASCUS or LSIL progressing to CIN2+ is still quite low, from 4% to 8% for ASCUS and 12% to 15% for LSIL \[[@R36]\]. The most widely adopted triage strategy for ASCUS is hrHPV testing. For young patients (\< 30 years old), because of the high prevalence of HPV, the test is less effective \[[@R37]\]. As well, because of the high HPV infection rates of LSIL patients -- 77% \[[@R38]\] to 80% \~ 85% \[[@R39]\] -- such patients need alternative triage methods.

We investigated the potential of using *JAM3*-M4 in triage of patients with ASCUS and LSIL. Both the specificity and PPV were increased as compared with hrHPV. *JAM3*-M4 could be especially used as a triage marker for patients \< 30 years old in light of the less effective triage performance of hrHPV testing in such patients. For LSIL patients, *JAM3*-M4 is ideal as a triage marker without loss of sensitivity and NPV. A proposed scheme for application of this methylation marker in triage is in Figure [7](#F7){ref-type="fig"}.

![Possible scenarios for the incorporation of a methylation test with JAM3-M4 in cervical cancer screening as a triage marker in (A) HrHPV testing or (B) cytology testing](oncotarget-06-44373-g007){#F7}

CIN lesions are divided into productive (CIN1 and CIN2) and transforming (CIN2 and CIN3) lesions. Productive CIN2 cannot be distinguished from transforming CIN2 by morphology assessment alone \[[@R23]\]. In our study, *JAM3*-M4 performed better with the CIN3+/CIN1− than CIN3+/CIN2− classification. Therefore, the methylation status of CIN2 is also mixed. At present, we lack a well-recognized gold standard to distinguish mixed CIN2. The updated guidelines \[[@R40]\] from the World Health Organization recommend immunohistochemistry analysis of P16 in biopsies to distinguish CIN2 as LSIL or HSIL. Therefore, we compared *JAM3*-M4 methylation status with P16 staining in CIN2 patients. Although results were not statistically significant, *JAM3*-M4 methylation status was still helpful for differentiating LSIL and HSIL.

Because the *JAM3* methylation marker we identified is specific to cervical cancer and discriminative among all diagnostic groups, the role of this gene in carcinogenesis is of interest. JAMs have been described as major components of tight junctions pivotal for establishing and maintaining cell polarity in endothelial and epithelial cells \[[@R41], [@R42]\]. During tumor development, they are remodeled, thereby allowing neoplastic cells to escape from constraints imposed by intercellular junctions and activate the cytoskeleton machinery into a pro-migratory state of the cell. Overexpression of *JAM3* in an epithelial carcinoma cell line improved tight junctions and restored an epithelial phenotype \[[@R43]\], and the expression was downregulated in gastric adenocarcinoma tissue \[[@R44]\]. *JAM3* promoted hematogenous lung metastasis in melanoma \[[@R45]\] and in an experimental metastatic model *in vivo* \[[@R46]\]. Therefore, its expression and participation vary in tumor cell--endothelial cell interactions in different tumor cells and the specific role in cervical carcinogenesis has not been studied. Investigating the role of *JAM3* in cervical carcinogenesis and whether and which role methylation may play in it would be of interest.

Our study contains some limitations. We examined methylation status in cervical scrapings from patients with a biopsy due to colposcopic abnormalities to avoid verification bias. This cohort was highly selected and was not representative of a screening population. Therefore, this marker may perform differently in a general population of asymptomatic women. Besides squamous cell carcinoma, other clinically important histological variants of cervical cancer, such as adenocarcinoma, exist. We have collected some but not many cervical scrapings of reactive or dysplastic glandular lesion in the cervix. However, *JAM3*-M4 will be further investigated if enough samples are available and may be found a biomarker.

Our study suggests that the *JAM3*-M4 methylation marker may be used as a triage marker for hrHPV-positive patients. For cytology testing, it is also an objective complementary marker, and its detection can be an effective triage strategy for patients with ASCUS, especially those who are \< 30 years old and those with LSIL. The performance of this marker should be further evaluated in a prospective, population-based study.

MATERIALS AND METHODS {#s4}
=====================

Ethics statement {#s4_1}
----------------

The investigation was conducted in accordance with the ethical standards and according to the Declaration of Helsinki and national and international guidelines and was approved by the authors\' institutional review board.

Patients {#s4_2}
--------

Frozen tissue specimens from 43 cervical cancer and 27 normal cervix were obtained from Qilu Hospital, Shandong University, from January to November 2013. Normal cervix tissue samples were obtained from patients without a history of abnormal cytology smears who planned to undergo hysterectomy for nonmalignant reasons, including fibroids, prolaps uteri, adenomyosis, hypermenorrhea or a combination of these. All cervical tissue was confirmed to be histopathologically normal.

QMSP analysis involved cervical scrapings taken under colposcopic guidance from February 2014 to January 2015 (P1) and July to September 2015 (P2). Samples were selected by random. The sample size was determined with respect to statistical calculation and feasibility and estimated on the basis of significance α, power 1-β and data from preliminary experiments. Only tissue from patients with confirmed histological diagnosis was included. The exclusion criteria were patients with a history of cervical neoplasia, cervix surgery, genital warts, an immunocompromised state, the presence of other cancers, or pregnancy. Histological diagnosis was assessed by 2 qualified pathologists in a blinded fashion. Informed consent was obtained from all patients and controls participating in this study. This study was approved by the ethics committee of Qilu Hospital, Shandong University.

Cytology testing and hrHPV testing {#s4_3}
----------------------------------

Cervical smears were cytomorphologically assessed in Thinprep Preservcyt medium (Hologic Inc, USA) by 2 qualified pathologists in a blinded fashion according to the Bethesda nomenclature \[[@R47]\].

Infection with hrHPV was detected by using HC2 kits (Qiagen GmbH, Germany). Samples with a relative light unit (RLU) ratio \> 1.0 were recorded as positive.

DNA extraction and bisulfite modification {#s4_4}
-----------------------------------------

Genomic DNA of frozen tissue and cervical scrapings was extracted by using the QlAamp DNA Mini Kit (Qiagen GmbH, Germany). Sodium bisulfate treatment of extracted genomic DNA involved use of EpiTect Bisulfite kits (Qiagen GmbH, Germany). The extracted DNA and modified DNA underwent PCR with primers for the house-keeping gene *GAPDH* (forward: AGGTCGGAGTCAACGGATTTG, reverse: GTGATGGCATGGACTGTGGT) and *β-actin* (forward: TGGTGATGGAGGAGGTTTAGTAAGT, reverse: AACCAATAAAACCTACTCCTCCCTTAA).

Methylation-sensitive PCR (MSP) and quantitative MSP (QMSP) {#s4_5}
-----------------------------------------------------------

MSP was performed on modified genomic DNA. Each PCR was performed in a final volume of 20 μL containing 5 μM each primer, 1 μL bisulfite-conversion DNA, and 1 × AmpliTaq Gold 360 Master Mix (ABI, USA). A sample was considered methylation-positive when a PCR product of the right size was visible after 40 cycles of PCR. The primers are in Table [6](#T6){ref-type="table"}.

###### MSP and QMSP primers

  Gene (locus)   Forward 5′--3′             Reverse 5′--3′         Fragment size (bp)   Tm (°C)
  -------------- -------------------------- ---------------------- -------------------- ---------
  *CADM1*-M2     GTTTTTCGTTATTTGTTGTTTTC    GAAACCGCGAAATACGAACG   117                  59
  *CADM1*-U2     GTTTTTTGTTATTTGTTGTTTTTG   AAAACCACAAAATACAAACA   117                  59
  *CADM1*-M8     GTCGTCGTATATTGGGATTC       TCTCATTAACTATCCGCTCG   110                  58
  *CADM1*-U8     GTTGTTGTATATTGGGATTT       TCTCATTAACTATCCACTCA   110                  58
  *DAPK1*-M2     CGTTTGTAGGGTTTTTATTGGTC    CTACCGCTACGAATTACCGA   161                  60
  *DAPK1*-U2     TGTTTGTAGGGTTTTTATTGGTTG   CCTACCACTACAAATTACCA   162                  60
  *DAPK1*-M3     GTTTTTATTGGTCGTTTGTC       GACGTTAACTCGATCCGACT   102                  58
  *DAPK1*-U3     TTTTATTGGTTGTTTGTTGG       CCCAACATTAACTCAATCCA   103                  58
  *JAM3*-M4      CGTAGTTAGGGTTGGGATTC       GAAATCCGACGACTATCCGA   138                  60
  *JAM3*-U4      TGTAGTTAGGGTTGGGATTT       CAAAATCCAACAACTATCCA   139                  60

Abbreviations: Tm: Annealing temperature

QMSP involved 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, 58--60°C for 1 min in a total volume of 20 μL based on the 7900HT Fast Real-Time PCR System (ABI, USA). The primers were identical to those for M markers used in MSP to evaluate the same locus of one gene. The final reaction mixture contained 50 nM each primer, 1 × Power SYBR Green PCR Master Mix (ABI, USA), and 1 μL bisulfite-converted genomic DNA.

EpiTect Control DNA and Control DNA Sets (QIAGEN, Germany; containing both bisulfite-converted methylated and unmethylated DNA, and unconverted unmethylated DNA) were used as MSP and QMSP control DNA. In addition, PCR of the bisulfite converted housekeeping gene β-actin was performed as a reference.

Each sample was analyzed in triplicate. Cycle threshold (Ct) ratios between the Ct values of the β-actin and target were used to quantify the level of methylation, calculated as 2^\[Ct\ (β-actin)\ -\ Ct\ (target)\]^ × 10,000. The cut-off value of QMSP for positivity/negativity was calculated and confirmed by receiver operating characteristic (ROC) analysis. Samples with Ct values for β-actin \> 32 were considered invalid and excluded from the analysis because they indicated poor DNA quality or recovery after bisulfite treatment.

Pyrosequencing {#s4_6}
--------------

Randomly selected samples of different groups underwent pyrosequencing to detect representative loci of *JAM3*-M4 with use of the PyroMark MD system (Qiagen GmbH, Germany) and the frequency of CpG methylation was measured by using PyroMark CpG software.

Immunohistochemistry {#s4_7}
--------------------

Sections (cervix scrapings and biopsy both collected during colposcopy) from patients histologically confirmed to have CIN2 were used to detect the expression of P16 (Dako, Denmark). Immunostaining involved use of the EnVision detection system (Dako, Denmark) according to the manufacturer\'s protocol.

Statistical analysis {#s4_8}
--------------------

Differences in detection rates between cervical cancer and normal cervical specimens by methylation markers were analyzed by chi-square or Fisher\'s exact test. ROC curves and their cut-off values were determined according to relative methylation levels obtained with QMSP. Pyrosequencing results were analyzed by Mann-Whitney test. Diagnostic performance for triage for methylation markers after hrHPV DNA and cytology testing was expressed as sensitivity, specificity, PPV and NPV with a cut-off for CIN2+ or CIN3+ respectively. All statistical analyses involved use of SPSS 18.0 (SPSS Inc., Chicago, IL, USA). P \<0.05 was considered statistically significant.
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